Rosetta Genomics Ltd (ROSG) 3.83 $ROSG Capricor cell

Rosetta Genomics Ltd (ROSG) 3.83 $ROSG

Capricor cell therapy candidate an Orphan Drug for Duchenne muscular dystrophy
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:56AM CDT

ROSG: 3.83 (-0.20), CAPR: 7.50 (+0.76), BMRN: 121.08 (-0.16), RNA: 18.65 (unch), PFE: 34.93 (+0.04), SRPT: 13.52 (+0.04), PTCT: 70.98 (unch), SMMT: 11.00 (-0.59)

How Energetic is Healthcare and How Healthy is The Energy Sector: Free Research on MediciNova, Cardica, Rosetta Genomics, Gulf Port Energy, Matador Resources
PR Newswire - Tue Apr 21, 9:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ROSG: 3.83 (-0.20), MNOV: 3.96 (-0.12), CRDC: 0.44 (+0.01), MTDR: 26.96 (+0.53), GPOR: 49.00 (-0.49)

Healthcare ratings roundup
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:42AM CDT

IPXL: 49.58 (-0.40), ROSG: 3.83 (-0.20), BCRX: 10.62 (-0.09), ALGN: 55.94 (-0.21), PAHC: 33.44 (+1.09), BMY: 66.60 (-0.21)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 8:17AM CDT

GENE: 4.88 (-0.05), ROSG: 3.83 (-0.20), HAS: 71.73 (-1.82), RCL: 73.23 (-0.68), FNRG: 3.11 (-0.86), ADRO: 38.17 (-0.50), CNDO: 4.09 (-0.09), AMPE: 2.89 (+0.20), NVGN: 7.40 (-0.30), HQCL: 2.20 (-0.01)

Rosetta Genomics Announces Data Published in Leukemia Research
Business Wire - Mon Apr 20, 7:30AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular and other diagnostics, announces that data highlighting its microRNA platform technology was published in Leukemia Research in an article entitled, "microRNA signature is indicative of long term prognosis in diffuse large B cell lymphoma." The article can be accessed online at www.lrjournal.com.
ROSG: 3.83 (-0.20)

Rosseta Genomics (ROSG) Stock Continues To Climb Today on Analyst Upgrade
at The Street - Fri Apr 17, 11:56AM CDT
Rosseta Genomics (ROSG) shares are climbing after analysts at Cantor upgraded the stock to 'buy' from 'hold' today.
ROSG: 3.83 (-0.20)

Rosetta Genomics secures U.S. patent covering second gen Cancer Origin Test
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 9:01AM CDT

ROSG: 3.83 (-0.20)

Rosetta Genomics (ROSG) Stock is Spiking on Receipt of Cancer Origin Test Patent
at The Street - Thu Apr 16, 9:54AM CDT
Rosetta Genomics (ROSG) shares are up double digits after the company announced that it received a patent for its cancer diagnostic assay.
ROSG: 3.83 (-0.20)

Rosetta Genomics Receives Key U.S. Patent Allowance for its Cancer of Origin Diagnostic Assay
Business Wire - Thu Apr 16, 8:15AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based assays, FISH testing and other molecular diagnostics, announces receipt of a Notice of Allowance for U.S. Patent Application No. 13/856,190, entitled, "Methods and materials for classification of tissue of origin of tumor samples."
ROSG: 3.83 (-0.20)

Rosetta Genomics Completes Acquisition of PersonalizeDx
Business Wire - Tue Apr 14, 7:30AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the closing of its acquisition of CynoGen, Inc. (d/b/a PersonalizeDx) from Prelude Corporation.
ROSG: 3.83 (-0.20)

Rosetta Genomics buys U.S.-based molecular diagnostics laboratory
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 11:41AM CDT

ROSG: 3.83 (-0.20)

Rosetta Genomics to Acquire PersonalizeDx
Business Wire - Thu Apr 09, 11:16AM CDT
--Enhances Rosetta Genomics' leadership as a provider of proprietary and differentiated content in the personalized medicine arena
ROSG: 3.83 (-0.20)

BUYINS.NET: WIP, MVO, ROSG, PIN Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Mar 27, 7:51AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SPDR DB International Government Inflation-Protected Bond ETF (NYSE:WIP), MV Oil Trust (NYSE:MVO), Rosetta Genomics Ltd (NASDAQ:ROSG), PowerShares India Exchange Traded Fund Trust (NYSEIN) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ROSG: 3.83 (-0.20), PIN: 22.28 (+0.20), MVO: 11.85 (-0.11), WIP: 55.58 (-0.25)

Rosetta Genomics up on patent award
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 8:13AM CDT

ROSG: 3.83 (-0.20)

Rosetta Genomics Receives Key U.S. Patent Allowance for its Novel Kidney Cancer Test
Business Wire - Thu Mar 26, 7:30AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance for U.S. Patent Application No. 13/412,020, entitled, "Gene Expression Signature for Classification of Kidney Tumors." The patent is owned jointly with Tel Hashomer Medical Research Ltd., the technology transfer company of the Chaim Sheba Medical Center in Israel.
ROSG: 3.83 (-0.20)

Rosetta Genomics to Launch Next-Generation Sequencing Panel from Admera Health
Business Wire - Wed Mar 25, 7:00AM CDT
--Will provide oncologists with unique solution of cutting-edge comprehensive genomic profiling and microRNA profiling to optimize therapeutic decision-making
ROSG: 3.83 (-0.20)

Rosetta Genomics' (ROSG) CEO Ken Berlin on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 17, 2:55PM CDT

ROSG: 3.83 (-0.20)

Rosetta Genomics announces 228% rise in 2014 revenues and double gross billings
M2 - Tue Mar 17, 4:46AM CDT
Molecular diagnostics company Rosetta Genomics (NasdaqCM:ROSG) stated on Monday that it recorded a net loss after discontinued operations of USD14.5m, or USD1.29 per ordinary share for the 12 months ended 31 December 2014.
ROSG: 3.83 (-0.20)